Colorectal Carcinoma MCQ — NEET PG Practice Question | NEETPGAI
Colorectal Carcinoma
medium
microscope Pathology
A 58-year-old man from Delhi presents with a 3-month history of altered bowel habits, blood-stained stools, and weight loss of 4 kg. Digital rectal examination reveals a hard, irregular mass 6 cm from the anal verge. Colonoscopy confirms a left-sided colonic mass with biopsy showing moderately differentiated adenocarcinoma. CT abdomen/pelvis shows no distant metastases. What is the most appropriate next step in management?
A. Endoscopic ultrasound and MRI pelvis for local staging
B. Neoadjuvant chemoradiation followed by surgery
C. Staging laparoscopy followed by chemotherapy
D. Immediate surgical resection without neoadjuvant therapy
Explanation
Clinical Assessment
This patient presents with a rectal adenocarcinoma (mass 6 cm from the anal verge, moderately differentiated) with no distant metastases on CT staging. The mass is within the rectum (defined as ≤15 cm from the anal verge), and at 6 cm it is in the mid-to-lower rectum. CT has already confirmed the absence of distant metastases.
Why Neoadjuvant Chemoradiation Followed by Surgery?
Key Point
For locally advanced rectal cancer (clinical T3/T4 or node-positive disease), the standard of care per NCCN, ESMO, and Indian guidelines is neoadjuvant chemoradiation (long-course 5-FU/capecitabine-based CRT or short-course radiotherapy) followed by total mesorectal excision (TME) — not further local staging workup.
A mass that is hard, irregular, and palpable on DRE at 6 cm from the anal verge is clinically at least cT2–T3 by examination alone.
CT abdomen/pelvis has already excluded distant metastases (M0 disease confirmed).
The clinical presentation (altered bowel habits, rectal bleeding, 4 kg weight loss, hard irregular mass) is consistent with locally advanced rectal cancer requiring downstaging before surgery.
Neoadjuvant CRT achieves tumor downstaging, sphincter preservation, improved local control, and reduced circumferential resection margin (CRM) positivity — all critical for rectal cancers in this location.
High-Yield (Harrison's / NCCN): For rectal cancers that are clinically T3/T4 or node-positive, neoadjuvant chemoradiation is the first treatment step after confirming M0 status. Surgery (TME) follows 6–8 weeks after completion of CRT.
Why Not Option D (EUS + MRI Pelvis)?
While EUS and MRI pelvis are valuable local staging tools, they are not the most appropriate next step in this clinical scenario:
The clinical and CT findings already indicate a locally advanced rectal cancer requiring neoadjuvant therapy.
In resource-limited settings (as implied by the Delhi context), additional local staging does not change the management decision when clinical staging already points to T3+ disease.
MRI pelvis alone (without EUS) is the preferred local staging modality per modern guidelines; EUS + MRI together is not the standard combination recommended as the "next step" when the clinical picture is already clear.
Delaying treatment for additional staging in a symptomatic, clinically advanced rectal cancer is not the best next step.
Why Not the Other Options?
B (Immediate surgery without neoadjuvant therapy): Incorrect. For locally advanced rectal cancer, direct surgery without neoadjuvant CRT leads to higher local recurrence rates and worse sphincter preservation outcomes.
C (Staging laparoscopy + chemotherapy): Incorrect. Staging laparoscopy is not indicated when CT has already excluded distant metastases. Chemotherapy alone (without radiation) is not standard neoadjuvant therapy for rectal cancer.
Clinical Pearl (KD Tripathi / NCCN): The rectum's proximity to the anal sphincter, mesorectal fascia, and pelvic sidewall makes neoadjuvant CRT essential for locally advanced tumors to achieve R0 resection and sphincter preservation. This is the cornerstone of modern rectal cancer management.
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
